In this study, we measured the proportion of peripheral Vδ2 T cells as well as the status and chemokine receptor expression profiles in SLE patients and healthy control (HC). In addition, Vδ2 T cell infiltration in the kidneys of patients with lupus nephritis was examined. The results showed that the percentage of peripheral Vδ2 T cells in new-onset SLE was decreased, and negatively correlated with the SLE Disease Activity Index score and the severity of proteinuria. These cells had a decreased apoptosis but an increased proliferation, and they showed increased accumulation in SLE kidneys. Moreover, IL-21 production and CD40L, CCR4, CCR7, CCR8, CXCR1 and CX3CR1 expression in Vδ2 T cells from SLE patients was significantly higher than from HC (p < 0.05), and these factors were downregulated in association with the repopulation of peripheral Vδ2 T cells in patients who were in remission (p < 0.05). In addition, anti-TCR Vδ2 antibodies activation significantly upregulated these chemokine receptors on Vδ2 T cells from HC, and this effect was blocked by inhibitors of PLC-γ1, MAPK/Erk, and PI3K signaling pathways. Our findings demonstrate that the distribution and function status of Vδ2 T cells from SLE patients are abnormal, and these aberrations may contribute to disease pathogenesis.
Scientific RepoRts | 5:14432 | DOi: 10.1038/srep14432 predominantly been investigated in tumor immunosurveillance and the host defense against viral invasion [10] [11] [12] [13] . The precise role of Vδ 2 T cells in the pathogenesis of SLE remains elusive. SLE is a systemic autoimmune disease characterized by autoantibody production and deposition in tissues and organs 14, 15 . T cells play an important role in inducing B cell hyperactivity 16, 17 . Activated T cells express CD40L 18 , and the engagement of CD40L with CD40 on B cells promotes immunoglobulin (Ig) secretion and isotype switching 19 . Activated T cells also secrete IL-21, which plays a major role in co-stimulating B cells 20, 21 . Studies have also shown that Vδ 2 T cells from both peripheral blood and secondary lymphoid tissues express costimulatory factors, including inducible costimulator (ICOS) and CD40L, and produce Th2-type cytokines such as IL-4 and IL-10 [22] [23] [24] . Coculture with activated Vδ 2 T cells resulted in a substantial increase in the B cell-mediated production of IgG, IgA, and IgM 25 , suggesting that Vδ 2 T cells may participate in a B cell hyperactivity network in SLE.
The local recruitment of inflammatory cells is also involved in tissue injury in SLE 26, 27 . The in situ expression levels of the Vδ 2 TCR + and Vγ 9 TCR + were found to be higher in the skin of SLE patients and positively correlated with disease activity 28 . As Vδ 2 T cells are primarily found in the peripheral blood, we were interested in exploring whether Vδ 2 T cells can induce B cell hyperactivity to produce autoantibodies and whether Vδ 2 T cells can be recruited to local tissues to directly participate in tissue injury in SLE.
In this study, we found that the number of circulating Vδ 2 T cells in the peripheral blood of new-onset SLE patients was significantly reduced and negatively correlated with the SLE Disease Activity Index (SLEDAI) score and the severity of proteinuria. However, this reduction in circulating Vδ 2 T cells was not caused by either increased apoptosis or decreased proliferation. Rather, we found a substantial accumulation of Vδ 2 T cells in the kidneys of SLE patients. In addition, the expression profile of chemokine receptors on Vδ 2 T cells was examined, and we found that the CCR4, CCR7, CCR8, CXCR1, CX3CR1, and CD40 L expression levels as well as IL-21 secretion by Vδ 2 T cells were significantly elevated in SLE patients and were downregulated after treatment with corticosteroids and immunosuppressants. A mechanistic study showed that upon activation by an anti-TCR Vδ 2 antibody, the expression levels of CCR4, CCR7, CCR8, CXCR1 and CX3CR1 on Vδ 2 T cells were significantly increased. Additionally, this effect was blocked by PLC-γ 1, MAPK/Erk, and PI3K inhibitors. Collectively, these data suggested that Vδ 2 T cells can overexpress CD40L and IL-21, induce B cell hyperactivity, migrate to local tissues and act as inflammatory cells to directly participate in tissue injury in SLE, leading to disease exacerbation.
Results
Peripheral Vδ2 T cells were decreased in new-onset SLE patients. We first compared the percentages of total peripheral γ δ T cells and the Vδ 1 and Vδ 2 T subsets between new-onset SLE patients and HC. Our results showed that there was a significant decrease in the percentage of total γ δ T cells in the peripheral blood of new-onset SLE patients (2.61 ± 1.79% vs. HC 8.35 ± 3.91%, p< 0.01) (Fig. 1A) . This decrease was primarily due to a reduction in Vδ 2 T cells (1.15± 0.94% vs. HC 6.31 ± 3.55%, p < 0.01) but not in Vδ 1 T cells (1.93 ± 1.55 vs. HC 2.49 ± 1.28, p = 0.291) (Fig. 1B,C) . The absolute numbers of Vδ 2 T cells in new-onset SLE patients was also lower than that in HC (134.3 ± 16.2 vs. HC 414.5 ± 57.3, p < 0.01).
Decreased apoptosis and increased proliferation of Vδ2 T cells in new-onset SLE patients. To examine why peripheral Vδ 2 T cells were reduced in SLE patients, we first measured the apoptosis and proliferation rates of these cells. By performing Annexin V/7-AAD double-staining flow cytometric analysis, we found that the apoptosis rate of peripheral Vδ 2 T cells in new-onset SLE patients was not increased but rather was decreased compared with that in HC (0.86 ± 0.27% vs. 1.66 ± 0.46%, p < 0.01) ( Fig. 2A) . In addition, the proliferation rate of Vδ 2 T cells in new-onset SLE patients was significantly increased compared with that in HC (83.97 ± 8.26% vs. 70.27 ± 7.55%, p < 0.01) (Fig. 2B) . When we assessed the activation status of Vδ 2 T cells, we found that most Vδ 2 T cells secreted IFN-γ and TNF-α and that the Vδ 2 T cell-mediated production of IFN-γ and TNF-α in SLE patients did not differ from that in HC (Fig. 2C) . These data collectively suggested that the peripheral reduction in Vδ 2 T cells was probably due to other causes, such as increased recruitment of these cells to local tissues.
Percentage of peripheral Vδ2 T cells negatively correlated with disease activity and the severity of proteinuria. The percentage of peripheral Vδ 2 T cells in SLE patients negatively correlated with disease activity, as determined by the SLEDAI score (r = − 0.656, p = 0.008, Fig. 3A ), but not with the titer of anti-dsDNA autoantibodies or the serum C3 levels (p > 0.05, Fig. 3B,C) . Notably, the percentage of Vδ 2 T cells significantly correlated with the severity of nephritis, which manifested as proteinuria (p < 0.05, Fig. 3D ).
Increased CD40L expression and IL-21 production by Vδ2 T cells from SLE patients. To determine whether Vδ 2 T cells can induce B cell hyperactivation by upregulating costimulatory factors, we examined the CD40L expression and IL-21 production abilities of Vδ 2 T cells. Our results showed that CD40L was primarily expressed by Vδ 2 T cell subsets that had low TCR Vδ 2 expression and that the level of CD40L expression by Vδ 2 T cells from SLE patients was significantly higher than from HC (51.05 ± 13.04% vs. 24.80 ± 4.25%, p < 0.01) (Fig. 4A,B) . The percentage of Vδ 2 T cells that were positive for intracellular IL-21 in SLE patients was significantly higher than in HC (51.69 ± 5.35% vs. 40. 52 ± 4.32%, p < 0.05) (Fig. 4A,B) .
Aberrant chemokine receptor expression profiles in Vδ2 T cells from SLE patients. Chemokine receptors, including CCR1-10, CXCR1-6 and CX3CR1, play a central role in cell trafficking to local tissues. Thus, we investigated the chemokine receptor expression profile of Vδ 2 T cells. Our results showed that in SLE patients, CCR4, CCR7, CCR8, CXCR1 and CX3CR1 expressed on Vδ 2 T cells were significantly higher than Vδ 1 T cells (p < 0.05) ( Fig. 5A-D) . In addition, the expression levels of CCR4, CCR7, CCR8, CXCR1 and CX3CR1 by Vδ 2 T cells from SLE patients were significantly higher than those from HC (p < 0.05) (Fig. 5C,D) , suggesting increased Vδ 2 T cell trafficking to local tissues in SLE patients. This hypothesis was confirmed by an immunohistochemical assay demonstrating an increase in the accumulation of Vδ 2 T cells in the kidneys of patients with lupus nephritis (Fig. 5E ).
Anti-TCR Vδ2 activating antibodies significantly upregulated chemokine receptor expression in Vδ2 T cells. To investigate whether activation of Vδ 2 T cells could induce upregulation of chemok-
ine receptors, we stimulated Vδ 2 T cells with anti-TCR Vδ 2 activating antibodies, and found that the expression levels of CCR4, CCR7, CCR8, CXCR1 and CX3CR1 on Vδ 2 T cells were upregulated by immobilized anti-TCR Vδ 2 antibodies but not IgG1 isotype control (Fig. 6A ). Three important signal pathways, PLC-γ 1, MAPK/Erk, and PI3K, are involved in T cell activation 29 . So we applied U73122 (PLC-γ 1 inhibitor), UO126 (MAPK/Erk inhibitor), and LY294002 (PI3K inhibitor), and investigated their roles in the upregulation of chemokine receptors on activated Vδ 2 T cells, and we found each signaling inhibitor completely abrogated the upregulation of chemokine receptors on Vδ 2 T cells (Fig. 6B) .
Repopulation of peripheral Vδ2
T cells with downregulated levels of chemokine receptors and costimulatory factors in remission SLE patients after treatment. In SLE patients who were in remission after treatment with corticosteroids and immunosuppressant, the expression levels of CCR4, CCR7, CCR8, CXCR1 and CX3CR1 on Vδ 2 T cells were downregulated (Fig. 7A) , and the percentage of peripheral Vδ 2 T cells was increased but did not return to normal ( Figs 1C and 7B) . Moreover, the Vδ 2 T cell-mediated expression of CD40L and production of IL-21 were downregulated in SLE patients after treatment (15.06 ± 6.04% vs. 51.06 ± 13.04% and 27.69 ± 5.35% vs. 51.69 ± 13.04%, respectively, p < 0.05) (Fig. 7C-D) .
Discussion
Although there have been a few studies investigating γ δ T cells in SLE patients, the results have been inconsistent 8, 30, 31 . One of the reasons may be that all of the previous studies examined total peripheral γ δ T cells without dissecting Vδ 1 and Vδ 2 T cells, even though these two cell types are phenotypically and functionally distinct, as Vδ 1 T cells are immunoregulatory and Vδ 2 T cells are inflammatory 5 . By examining new-onset patients, our study demonstrated that the number of peripheral γ δ T cells was significantly decreased due to a reduction in Vδ 2 T cells but not in Vδ 1 T cells. In addition, we found that the decrease in Vδ 2 T cells was not caused by either increased apoptosis or impaired proliferation. Rather, the apoptosis rate was decreased and the proliferation rate was increased, suggesting an abnormal overgrowth of inflammatory Vδ 2 T cells in SLE.
In this study, we found that the reduction in Vδ 2 T cells correlated with the severity of proteinuria and that Vδ 2 T cell infiltration into the kidneys was increased in patients with lupus nephritis, suggesting that Vδ 2 T cells are abnormally recruited to tissues to participate in tissue damage in SLE patients. In fact, the recruitment of γ δ T cells (including Vδ 2 T cells) to local organs and tissues has been reported in some diseases 28, [32] [33] [34] [35] [36] [37] [38] [39] . Selective Vδ 2 T cell homing from the blood to tissues is controlled by a multi-step process involving interactions between chemokines and chemokine receptors. Jiang et al. reported that the accumulation of γ δ T cells in the embryo is CCR4-dependent 40 . During an allergic reaction, CCL25 drives the mobilization of IL-17 + γ δ T cells to inflamed tissue 34 . Additionally, through CCL2-CCR2 interactions, γ δ T cells can be recruited during allergic inflammation 41 . Our study demonstrated that Vδ 2 T cells express a variety of chemokine receptors and that the expression levels of CCR4, CCR7, CCR8, CXCR1 and CX3CR1 on Vδ 2 T cells are upregulated in new-onset SLE patients. Similar to the abnormal activation state of Vδ 2 T cells in SLE patients, we found that antibody-induced T cell stimulation significantly upregulated the expression levels of CCR4, CCR7, CCR8, CXCR1 and CX3CR1 on Vδ 2 T cells from HC. In SLE patients in remission after effective treatment with glucocorticoids and immunosuppressant, the overexpression of these chemokine receptors was rectified in association with the repopulation of peripheral Vδ 2 T cells, further supporting the abnormal local trafficking of these inflammatory Vδ 2 T cells in SLE patients.
The hyperactivation and dysfunction of B cells, which ultimately leads to the massive production of autoantibodies, is the major pathological event in SLE 42 . CD40L, IL-21, and other costimulatory factors such as ICOS play pivotal roles in controlling B cell homeostasis and function, and numerous reports have suggested that the abnormal regulation of CD40L, IL-21, and ICOS is implicated in B cell hyperactivation in SLE 22, 42, 43 . Previous studies showed that Vδ 2 T cells from both peripheral blood and secondary lymphoid tissues express both ICOS and CD40L 22 and produce Th2-type cytokines such as IL-4 and IL-10 23, 24 . Our results showed that Vδ 2 T cells from SLE patients overexpressed CD40L and produced increased levels of IL-21, which were downregulated during remission after treatment, suggesting that Vδ 2 T cells are important in promoting B cell hyperactivation in SLE. In addition, via the upregulation of CCR4, CCR7, CCR8, CXCR1 and CX3CR1, these inflammatory Vδ 2 T cells were abnormally recruited to local tissues, such as the kidneys, to participate in tissue damage and contribute to disease pathogenesis in SLE.
In summary, this study demonstrated that the percentage of peripheral Vδ 2 T cells decreased significantly in new-onset active SLE patients. As these cells exhibited a decreased apoptosis rate, an increased proliferation rate, and upregulated levels of costimulatory factors including CD40L and IL-21, we suggest that these overgrown and hyperactive inflammatory Vδ 2 T cells are increasingly recruited to tissues via 
Materials and Methods

Patients and controls. This study was approved by the Institutional Review Board of Peking Union
Medical College Hospital and written informed consent was obtained from each participating patient and healthy control (HC). And the methods were carried out in accordance with the approved guidelines. Fifteen patients with new-onset SLE (including 14 females and 1 male; mean age 24.8 y; range 14-40 y; Table 1 ) from Peking Union Medical College (PUMC) Hospital were enrolled in this study, and peripheral blood samples were collected from these patients before and after treatment with glucocorticoids and immunosuppressant. All patients fulfilled the revised American College of Rheumatology criteria for SLE. Lupus disease activity was evaluated using the SLEDAI score (before treatment: mean 10.4, range 3-16; after treatment: 0-3). Peripheral blood samples were also collected from 15 healthy subjects as controls (HC) (14 females and 1 male; mean age 27 y; range 19-38 y).
Antibodies and reagents. RPMI APC-conjugated anti-human CCR2 (K036C2), PE-conjugated anti-human CCR3 (5E8), APC-conjugated anti-human CCR4 (L291H4), APC-conjugated anti-human CCR5 (J418F1), PE-conjugated anti-human CCR6 (G034E3), APC-conjugated anti-human CCR7 (G043H7), PE-conjugated anti-human CCR8 (L263G8), APC-conjugated anti-human CCR9 (L053E8), PE-conjugated anti-human CCR10 (6588-5), APC-conjugated anti-human CXCR1 (8F1/CXCR1), PE-conjugated anti-human CXCR2 (5E8/CXCR2), APC-conjugated anti-human CXCR3 (G025H7), PE-conjugated anti-human CXCR4 (12G5), PE-conjugated anti-human CXCR5 (J252D4), PE-conjugated anti-human CXCR6 (K041E5), PE-conjugated anti-human CX3CR1 (2A9-1) and Cell Activation Cocktail (with Brefeldin A) were purchased from Biolegend; the purified anti-TCR Vδ 2 antibody (15D) was obtained from Abcam; FITC-conjugated anti-human TCR Vδ 1 (TS8.2) was obtained from Pierce; CellTrace ™ CFSE Cell Proliferation Kit was purchased from
Invitrogen; and U73122, UO126, LY294002, phorbol myristate acetate (PMA) and ionomycin (Ion) were obtained from Sigma.
Cells.
Human peripheral blood mononuclear cells (PBMCs) from SLE patients and HC were collected in sodium heparin tubes (BD) and were purified via Ficoll-Hypaque (TBD, Tianjin, China) density gradient centrifugation. For the activation assay, fresh Vδ 2 T cells (> 90%) were purified by positive selection using an anti-FITC microbeads (MiltenyiBiotec), and then cultured in RPMI 1640 medium containing 10% fetal calf serum FBS in 24-well culture plates coated with 2 μ g/ml anti-TCR Vδ 2 antibody. After 4 days in culture, the expression levels of chemokine receptors were analyzed via flow cytometric analysis. Annexin V Binding Buffer was added to each tube. The stained cells were immediately analyzed with a BD Accuri C6 flow cytometer (Becton Dickinson). Data analysis was performed using FlowJo Software (Tree Star Inc.).
Immunohistochemistry assay. Immunohistochemical staining was performed at the Department of Pathology Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. To block endogenous peroxidase activity, the samples were treated with 1.5% H 2 O 2 for 20 min. Then, the slides were washed with TBS 3 times for 3 minutes each. Non-specific binding sites were blocked with 10% diluted goat serum in TBS for 20 hours. The samples were incubated overnight at 4 °C in the appropriate antibody dilution (1:5). The slides were washed 5 times in TBS and incubated in the anti-mouse IgG peroxidase antibody for 1 hour. The slides were washed 5 times in TBS. Avidin-biotin-peroxidase reagents were added, and the resulting peroxidase activity was revealed by incubating the slides in a 0.5 mg/mL HRP substrate solution (DAB + H 2 O 2 prepared in distilled water). The slides were washed 5 times in TBS and counterstained for 1 minute with hematoxylin. The slides were dehydrated by washing the slides in an ethanol series for 1 minute each in 75%, 80% and, finally, 100% ethanol. Statistical analysis. All data were analyzed using SPSS 16.0 software. The results are expressed as the means ± SD, and one-way analyses of variance were used to compare data displaying a normal distribution and homogeneity of variance. Independent-sample t-tests were used to compare differences between two groups and differences before and after treatment. Correlations were calculated using Pearson's correlation analysis. In all analyses, the minimum acceptable level of significance was p < 0.05.
